<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p84" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_84{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_84{left:341px;bottom:30px;}
#t3_84{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_84{left:377px;bottom:30px;}
#t5_84{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_84{left:540px;bottom:30px;}
#t7_84{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_84{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_84{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_84{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_84{left:285px;bottom:827px;letter-spacing:-0.37px;word-spacing:0.11px;}
#tc_84{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_84{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_84{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_84{left:1115px;bottom:47px;letter-spacing:0.36px;}
#tg_84{left:1121px;bottom:28px;letter-spacing:0.21px;word-spacing:-0.15px;}
#th_84{left:1083px;bottom:83px;letter-spacing:-0.1px;}
#ti_84{left:374px;bottom:778px;letter-spacing:0.35px;word-spacing:-0.19px;}
#tj_84{left:107px;bottom:725px;letter-spacing:-0.12px;word-spacing:0.02px;}
#tk_84{left:107px;bottom:707px;letter-spacing:-0.09px;}
#tl_84{left:107px;bottom:682px;letter-spacing:-0.09px;}
#tm_84{left:107px;bottom:632px;letter-spacing:-0.1px;}
#tn_84{left:107px;bottom:614px;letter-spacing:-0.1px;}
#to_84{left:107px;bottom:582px;letter-spacing:-0.11px;}
#tp_84{left:107px;bottom:564px;letter-spacing:-0.08px;}
#tq_84{left:268px;bottom:571px;}
#tr_84{left:107px;bottom:545px;letter-spacing:-0.09px;}
#ts_84{left:416px;bottom:553px;}
#tt_84{left:429px;bottom:545px;letter-spacing:-0.09px;}
#tu_84{left:107px;bottom:527px;letter-spacing:-0.1px;word-spacing:0.02px;}
#tv_84{left:118px;bottom:509px;letter-spacing:-0.09px;word-spacing:-0.31px;}
#tw_84{left:277px;bottom:516px;}
#tx_84{left:107px;bottom:490px;letter-spacing:-0.08px;}
#ty_84{left:278px;bottom:498px;letter-spacing:-0.12px;}
#tz_84{left:107px;bottom:472px;letter-spacing:-0.09px;}
#t10_84{left:299px;bottom:479px;}
#t11_84{left:607px;bottom:582px;letter-spacing:-0.09px;}
#t12_84{left:607px;bottom:564px;}
#t13_84{left:617px;bottom:564px;letter-spacing:-0.09px;word-spacing:-0.15px;}
#t14_84{left:612px;bottom:545px;}
#t15_84{left:629px;bottom:545px;letter-spacing:-0.09px;}
#t16_84{left:708px;bottom:553px;}
#t17_84{left:612px;bottom:527px;}
#t18_84{left:629px;bottom:527px;letter-spacing:-0.09px;}
#t19_84{left:725px;bottom:534px;}
#t1a_84{left:612px;bottom:509px;}
#t1b_84{left:629px;bottom:509px;letter-spacing:-0.09px;}
#t1c_84{left:716px;bottom:516px;}
#t1d_84{left:612px;bottom:490px;}
#t1e_84{left:629px;bottom:490px;letter-spacing:-0.09px;}
#t1f_84{left:806px;bottom:498px;letter-spacing:-0.26px;}
#t1g_84{left:607px;bottom:472px;letter-spacing:-0.11px;}
#t1h_84{left:668px;bottom:472px;letter-spacing:-0.08px;}
#t1i_84{left:753px;bottom:472px;letter-spacing:-0.13px;}
#t1j_84{left:803px;bottom:472px;letter-spacing:-0.09px;}
#t1k_84{left:612px;bottom:454px;}
#t1l_84{left:629px;bottom:454px;letter-spacing:-0.08px;}
#t1m_84{left:721px;bottom:461px;letter-spacing:-0.13px;}
#t1n_84{left:612px;bottom:435px;}
#t1o_84{left:629px;bottom:435px;letter-spacing:-0.08px;}
#t1p_84{left:708px;bottom:443px;letter-spacing:-0.14px;}
#t1q_84{left:607px;bottom:417px;}
#t1r_84{left:617px;bottom:417px;letter-spacing:-0.1px;}
#t1s_84{left:930px;bottom:424px;}
#t1t_84{left:612px;bottom:399px;}
#t1u_84{left:629px;bottom:399px;letter-spacing:-0.17px;}
#t1v_84{left:726px;bottom:406px;letter-spacing:-0.1px;}
#t1w_84{left:612px;bottom:380px;}
#t1x_84{left:629px;bottom:380px;letter-spacing:-0.1px;}
#t1y_84{left:906px;bottom:388px;letter-spacing:-0.14px;}
#t1z_84{left:612px;bottom:362px;}
#t20_84{left:629px;bottom:362px;letter-spacing:-0.13px;}
#t21_84{left:820px;bottom:369px;letter-spacing:-0.12px;}
#t22_84{left:612px;bottom:344px;}
#t23_84{left:629px;bottom:344px;letter-spacing:-0.09px;}
#t24_84{left:801px;bottom:351px;letter-spacing:-0.12px;}
#t25_84{left:612px;bottom:325px;}
#t26_84{left:629px;bottom:325px;letter-spacing:-0.1px;}
#t27_84{left:884px;bottom:333px;letter-spacing:-0.14px;}
#t28_84{left:607px;bottom:307px;letter-spacing:-0.09px;}
#t29_84{left:795px;bottom:314px;letter-spacing:-0.14px;}
#t2a_84{left:607px;bottom:289px;letter-spacing:-0.08px;}
#t2b_84{left:777px;bottom:296px;letter-spacing:-0.14px;}
#t2c_84{left:607px;bottom:270px;}
#t2d_84{left:617px;bottom:270px;letter-spacing:-0.09px;word-spacing:-0.15px;}
#t2e_84{left:933px;bottom:278px;letter-spacing:-0.14px;}
#t2f_84{left:607px;bottom:252px;letter-spacing:-0.09px;word-spacing:-0.18px;}
#t2g_84{left:863px;bottom:259px;letter-spacing:-0.14px;}
#t2h_84{left:607px;bottom:234px;}
#t2i_84{left:617px;bottom:234px;letter-spacing:-0.08px;}
#t2j_84{left:618px;bottom:215px;letter-spacing:-0.09px;word-spacing:-0.04px;}
#t2k_84{left:1094px;bottom:223px;letter-spacing:-0.14px;}
#t2l_84{left:607px;bottom:197px;letter-spacing:-0.08px;}
#t2m_84{left:807px;bottom:197px;letter-spacing:-0.1px;}
#t2n_84{left:856px;bottom:197px;letter-spacing:-0.09px;}
#t2o_84{left:1025px;bottom:204px;letter-spacing:-0.14px;}
#t2p_84{left:607px;bottom:179px;letter-spacing:-0.08px;}
#t2q_84{left:743px;bottom:179px;letter-spacing:-0.13px;}
#t2r_84{left:782px;bottom:179px;letter-spacing:-0.09px;}
#t2s_84{left:987px;bottom:186px;letter-spacing:-0.14px;}
#t2t_84{left:36px;bottom:148px;}
#t2u_84{left:46px;bottom:142px;letter-spacing:0.12px;word-spacing:-0.1px;}
#t2v_84{left:45px;bottom:125px;letter-spacing:0.12px;word-spacing:-0.1px;}
#t2w_84{left:36px;bottom:114px;}
#t2x_84{left:46px;bottom:108px;letter-spacing:0.12px;}
#t2y_84{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_84{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_84{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_84{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_84{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_84{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_84{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_84{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.s7_84{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s8_84{font-size:14px;font-family:ArialMT_5tg;color:#000;}
.s9_84{font-size:17px;font-family:ArialMT_k0;color:#000;}
.sa_84{font-size:17px;font-family:Webdings_k6;color:#000;}
.sb_84{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.sc_84{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.sd_84{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.se_84{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sf_84{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts84" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg84Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg84" style="-webkit-user-select: none;"><object width="1210" height="935" data="84/84.svg" type="image/svg+xml" id="pdf84" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_84" class="t s0_84">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_84" class="t s1_84">® </span>
<span id="t3_84" class="t s0_84">(NCCN </span>
<span id="t4_84" class="t s1_84">® </span>
<span id="t5_84" class="t s0_84">), All rights reserved. NCCN Guidelines </span>
<span id="t6_84" class="t s1_84">® </span>
<span id="t7_84" class="t s0_84">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_84" class="t s2_84">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_84" class="t s2_84">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_84" class="t s3_84">NCCN Guidelines Version 4.2024 </span>
<span id="tb_84" class="t s3_84">Salivary Gland Tumors </span>
<span id="tc_84" class="t s4_84">NCCN Guidelines Index </span>
<span id="td_84" class="t s4_84">Table of Contents </span>
<span id="te_84" class="t s4_84">Discussion </span>
<span id="tf_84" class="t s5_84">SALI-B </span>
<span id="tg_84" class="t s5_84">1 OF 2 </span>
<span id="th_84" class="t s6_84">References </span>
<span id="ti_84" class="t s5_84">SYSTEMIC THERAPY FOR SALIVARY GLAND TUMORS </span>
<span id="tj_84" class="t s5_84">Recurrent, Unresectable, or Metastatic Salivary Gland Tumors </span>
<span id="tk_84" class="t s5_84">(with no surgery or RT option) </span>
<span id="tl_84" class="t s5_84">• The choice of systemic therapy should be individualized based on patient characteristics (eg, PS, goals of therapy). </span>
<span id="tm_84" class="t s5_84">Preferred Regimens </span>
<span id="tn_84" class="t s7_84">• None </span>
<span id="to_84" class="t s5_84">Other Recommended Regimens </span>
<span id="tp_84" class="t s7_84">• Cisplatin/vinorelbine </span>
<span id="tq_84" class="t s8_84">1 </span>
<span id="tr_84" class="t s7_84">• Cisplatin/doxorubicin/cyclophosphamide </span>
<span id="ts_84" class="t s8_84">2 </span>
<span id="tt_84" class="t s7_84">(category 2B) </span>
<span id="tu_84" class="t s7_84">• Paclitaxel (category 2A for non-adenoid cystic carcinoma [ACC]; </span>
<span id="tv_84" class="t s7_84">category 2B for ACC) </span>
<span id="tw_84" class="t s8_84">3 </span>
<span id="tx_84" class="t s7_84">• Carboplatin/paclitaxel </span>
<span id="ty_84" class="t s8_84">4,5 </span>
<span id="tz_84" class="t s7_84">• Carboplatin/gemcitabine </span>
<span id="t10_84" class="t s8_84">6 </span>
<span id="t11_84" class="t s5_84">Useful in Certain Circumstances </span>
<span id="t12_84" class="t s7_84">• </span><span id="t13_84" class="t s9_84">Androgen receptor (AR) therapy for AR+ tumors </span>
<span id="t14_84" class="t sa_84"></span><span id="t15_84" class="t s7_84">Leuprolide </span>
<span id="t16_84" class="t s8_84">7 </span>
<span id="t17_84" class="t sa_84"></span><span id="t18_84" class="t s7_84">Bicalutamide </span>
<span id="t19_84" class="t s8_84">8 </span>
<span id="t1a_84" class="t sa_84"></span><span id="t1b_84" class="t s7_84">Abiraterone </span>
<span id="t1c_84" class="t s8_84">9 </span>
<span id="t1d_84" class="t sa_84"></span><span id="t1e_84" class="t s7_84">Goserelin (category 2B) </span>
<span id="t1f_84" class="t s8_84">10,11,12 </span>
<span id="t1g_84" class="t sb_84">• NTRK </span><span id="t1h_84" class="t s7_84">therapy for </span><span id="t1i_84" class="t sb_84">NTRK </span><span id="t1j_84" class="t s7_84">gene fusion-positive tumors </span>
<span id="t1k_84" class="t sa_84"></span><span id="t1l_84" class="t s7_84">Larotrectinib </span>
<span id="t1m_84" class="t s8_84">13,14 </span>
<span id="t1n_84" class="t sa_84"></span><span id="t1o_84" class="t s7_84">Entrectinib </span>
<span id="t1p_84" class="t s8_84">15 </span>
<span id="t1q_84" class="t s7_84">• </span><span id="t1r_84" class="t s9_84">HER2-targeted therapy for HER2+ tumors </span>
<span id="t1s_84" class="t s8_84">a </span>
<span id="t1t_84" class="t sa_84"></span><span id="t1u_84" class="t s9_84">Trastuzumab </span>
<span id="t1v_84" class="t s8_84">b,16 </span>
<span id="t1w_84" class="t sa_84"></span><span id="t1x_84" class="t s9_84">Ado-trastuzumab emtansine (TDM-1) </span>
<span id="t1y_84" class="t s8_84">17 </span>
<span id="t1z_84" class="t sa_84"></span><span id="t20_84" class="t s9_84">Trastuzumab/pertuzumab </span>
<span id="t21_84" class="t s8_84">b,18 </span>
<span id="t22_84" class="t sa_84"></span><span id="t23_84" class="t s9_84">Docetaxel/trastuzumab </span>
<span id="t24_84" class="t s8_84">b,19 </span>
<span id="t25_84" class="t sa_84"></span><span id="t26_84" class="t s9_84">Fam-trastuzumab deruxtecan-nxki </span>
<span id="t27_84" class="t s8_84">20 </span>
<span id="t28_84" class="t s7_84">• Sorafenib (category 2B) </span>
<span id="t29_84" class="t s8_84">21 </span>
<span id="t2a_84" class="t s7_84">• Axitinib (category 2B) </span>
<span id="t2b_84" class="t s8_84">22 </span>
<span id="t2c_84" class="t s7_84">• </span><span id="t2d_84" class="t s9_84">Axitinib + avelumab for ACC (category 2B) </span>
<span id="t2e_84" class="t s8_84">23 </span>
<span id="t2f_84" class="t s7_84">• Lenvatinib for ACC (category 2B) </span>
<span id="t2g_84" class="t s8_84">24 </span>
<span id="t2h_84" class="t s7_84">• </span><span id="t2i_84" class="t s9_84">Pembrolizumab (for microsatellite instability-high [MSI-H], </span>
<span id="t2j_84" class="t s9_84" data-mappings='[[18,"fi"]]'>mismatch repair deﬁcient [dMMR], TMB-H [≥10 mut/Mb] tumors) </span>
<span id="t2k_84" class="t s8_84">25 </span>
<span id="t2l_84" class="t s7_84">• Dabrafenib/trametinib for </span><span id="t2m_84" class="t sb_84">BRAF </span><span id="t2n_84" class="t s7_84">V600E-positive tumors </span>
<span id="t2o_84" class="t s8_84">26 </span>
<span id="t2p_84" class="t s7_84">• Selpercatinib for </span><span id="t2q_84" class="t sb_84">RET </span><span id="t2r_84" class="t s7_84">gene fusion-positive tumors </span>
<span id="t2s_84" class="t s8_84">27 </span>
<span id="t2t_84" class="t sc_84">a </span>
<span id="t2u_84" class="t sd_84">Refer to ASCO/CAP guidelines for HER2 testing (Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast </span>
<span id="t2v_84" class="t sd_84">cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol 2018;36:2105-2122). </span>
<span id="t2w_84" class="t sc_84">b </span>
<span id="t2x_84" class="t se_84">An FDA-approved biosimilar is an appropriate substitute for trastuzumab. </span>
<span id="t2y_84" class="t sf_84">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
